TroVax

Results: 20



#Item
12011 Annual Report 20 years of GI Cancer Research

2011 Annual Report 20 years of GI Cancer Research

Add to Reading List

Source URL: gicancer.org.au

Language: English - Date: 2013-01-14 19:04:01
2FO R U M DISCRIMINATING FACTORS IN TREATMENT DECISIONS FOR CHEMOTHERAPY IN ELDERLY PATIENTS WITH COLORECTAL CANCER

FO R U M DISCRIMINATING FACTORS IN TREATMENT DECISIONS FOR CHEMOTHERAPY IN ELDERLY PATIENTS WITH COLORECTAL CANCER

Add to Reading List

Source URL: www.cancerforum.org.au

Language: English - Date: 2009-05-12 10:00:00
3Reproduced from Expert Review of Anticancer Therapy, December 2009, Vol. 9, No. 12, Pages[removed]with permission of Expert Reviews Ltd Editorial For reprint orders, please contact [removed]

Reproduced from Expert Review of Anticancer Therapy, December 2009, Vol. 9, No. 12, Pages[removed]with permission of Expert Reviews Ltd Editorial For reprint orders, please contact [removed]

Add to Reading List

Source URL: usir.salford.ac.uk

Language: English - Date: 2011-10-13 04:41:52
4Understanding Clinical Trials  HR = 0.60 (CI : 0.51–0.70) p<0.0001

Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001

Add to Reading List

Source URL: www.roche.com

Language: English - Date: 2015-01-10 07:27:14
5Understanding Clinical Trials  HR = 0.60 (CI : 0.51–0.70) p<0.0001

Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001

Add to Reading List

Source URL: www.roche.com

Language: English - Date: 2014-05-27 02:22:43
6Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer

Add to Reading List

Source URL: hugin.info

Language: English - Date: 2012-12-09 11:48:23
7OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013 Oxford, UK – 10 April 2014: Oxford BioMedica plc (

OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013 Oxford, UK – 10 April 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical c

Add to Reading List

Source URL: www.oxfordbiomedica.co.uk

Language: English - Date: 2014-04-10 02:09:25
8GTSAB REPORT  Recombinant DNA Advisory Committee

GTSAB REPORT Recombinant DNA Advisory Committee

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-30 15:21:58
9Serious and Other Selected Adverse Events Reported for Human Gene Transfer Protocols Recombinant DNA Advisory Commitee Meeting December 2007 Protocol Number: Protocol Title:

Serious and Other Selected Adverse Events Reported for Human Gene Transfer Protocols Recombinant DNA Advisory Commitee Meeting December 2007 Protocol Number: Protocol Title:

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-10 09:36:57
10Serious and Other Selected Adverse Events Reported for Human Gene Transfer Protocols Recombinant DNA Advisory Commitee Meeting June 2007 Protocol Number:	 Protocol Title:

Serious and Other Selected Adverse Events Reported for Human Gene Transfer Protocols Recombinant DNA Advisory Commitee Meeting June 2007 Protocol Number: Protocol Title:

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-10 09:43:28